Syndax Pharmaceuticals Announced That Data From Phase 2 Portion Of The AUGMENT-101 Trial Of Revumenib In Adult And Pediatric Patients With Relapsed/Refractory KMT2A-rearranged Acute Myeloid Leukemia And Acute Lymphoid Leukemia Have Been Published In The Journal Of Clinical Oncology
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals announced the publication of data from the Phase 2 portion of the AUGMENT-101 trial of Revumenib in adult and pediatric patients with relapsed/refractory KMT2A-rearranged Acute Myeloid Leukemia and Acute Lymphoid Leukemia in the Journal of Clinical Oncology.
August 12, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals published promising Phase 2 trial data for Revumenib in the Journal of Clinical Oncology, targeting relapsed/refractory KMT2A-rearranged AML and ALL.
The publication of positive Phase 2 trial data in a reputable journal is likely to boost investor confidence in Syndax Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100